Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

NCT05225584 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hodgkin Lymphoma (NHL)
Peripheral T-cell Lymphoma (PTCL)
Cutaneous T-Cell Lymphoma (CTCL)
Large Granular Lymphocytic Leukemia (LGL-L)
T-cell Prolymphocytic Leukemia (T-PLL)
Solid Tumors

Interventions

DRUG: KT-333

Sponsor

Kymera Therapeutics, Inc.